Baxter International Inc.

Baxter International Inc. (Baxter) is a global health care company specializing in medical devices, pharmaceuticals and biotechnology. The company's products assist health care professionals and their patients with the treatment of complex medical conditions such as hemophilia, immune disorders, kidney disease, trauma and other conditions. The company's operations are concentrated in the US, Europe, Asia and Latin America. It is headquartered in Illinois, the US.Baxter generates revenues through three business divisions: BioScience (43.6% of the total revenues during fiscal year 2008), Medication Delivery (37.5%) and Renal (18.9%).The company classifies its geographic locations into five regions namely, United States; Europe; Latin America; Canada; and Asia & Other Countries. The United States (40.8% of the total revenues of the company for the fiscal year 2008), followed by Europe (35.5%); Asia & Other Countries (11.7%); Latin America (8.7%); and Canada (3.8%).Recently, Baxter entered into an agreement to acquire outstanding shares of ApaTech, a private equity-backed, UK based orthobiologic products company for $330 million. The company received marketing authorization for Celvapan H1N1 vaccine from European Commission. It signed a definitive agreement to acquire certain assets related to Edwards' hemofiltration product line, known as Continuous Renal Replacement Therapy (CRRT).The company reported revenues of (U.S. Dollars) USD 12,348.00 million during the fiscal year ended December 2008, an increase of 9.63% over 2007. The operating profit of the company was USD 2,549.00 million during the fiscal year 2008, an increase of 16.82% over 2007. The net profit of the company was USD 2,014.00 million during the fiscal year 2008, an increase of 17.98% over 2007.